TP53 Pathway Alterations Drive Radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG).

Coralie WerbrouckCláudia C S EvangelistaMaría-Jesús Lobón-IglesiasEmilie BarretGwénaël Le TeuffJane MerlevedeRomain BrusiniThomas KergrohenMichele MondiniStéphanie BollePascale VarletKevin BeccariaNathalie BoddaertStéphanie PugetJacques GrillMarie-Anne DebilyDavid Castel

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Here, we demonstrate that TP53 mutations are driving DIPG radioresistance both in patients and corresponding cellular models. We suggest alternative treatment strategies to mitigate radioresistance with CHK1 inhibitors. These findings will allow to consequently refine radiotherapy schedules in DIPG.

Keyphrases

dna damage response
end stage renal disease
newly diagnosed
ejection fraction
cancer stem cells
radiation therapy
prognostic factors
squamous cell carcinoma
oxidative stress
patient reported outcomes